The science of peptides has moved from the fringes of sports medicine into mainstream conversation remarkably quickly. Walk into any serious gym in 2026 and it will not be long before someone mentions BPC-157, CJC-1295, or one of a growing list of compounds that have earned a devoted following among athletes, bodybuilders, and fitness enthusiasts who feel they have exhausted what conventional supplementation can offer.

But what does the research actually say? Which peptides have meaningful human data behind them? Which remain largely theoretical, supported only by animal studies and compelling biochemistry? And — critically for anyone reading from the UK — what is the current legal and safety landscape?

This guide works through those questions systematically. It covers peptides relevant to four core fitness goals — muscle hypertrophy, fat loss and body recomposition, recovery and injury repair, and healthy ageing and hormonal optimisation — and examines each compound honestly, including what the evidence genuinely supports and where it falls short.

What Are Peptides and How Do They Work?

Peptides are short chains of amino acids — the same building blocks that make up proteins. The difference is scale: proteins can contain hundreds or thousands of amino acids, whereas peptides typically contain between two and fifty. Because of their smaller size, many peptides are able to act as precise signalling molecules, binding to specific receptors and triggering targeted biological responses.

Your body already produces thousands of peptides naturally. Hormones such as insulin, glucagon, and growth hormone are peptides. So are certain neurotransmitters and immune modulators. The synthetic peptides used in fitness and medicine are either direct analogues of naturally occurring molecules, or novel sequences designed to mimic or amplify specific pathways.

In the context of gym performance and body composition, the peptides that attract the most attention fall into a handful of mechanistic categories: those that stimulate growth hormone release, those that directly activate muscle growth signalling, those that accelerate tissue repair and recovery, and those that modulate fat metabolism.

Peptide Categories at a Glance

CJC-1295 — The Long-Acting GHRH Analogue

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), designed to bind to albumin in the bloodstream and thereby extend its working half-life from minutes to days. It stimulates the pituitary gland to release growth hormone in a sustained, dose-dependent manner, which in turn elevates insulin-like growth factor 1 (IGF-1) — the primary downstream driver of muscle protein synthesis.

A controlled human study published in the peer-reviewed literature confirmed that CJC-1295 produced sustained, dose-dependent increases in both GH and IGF-1 in healthy adults and was reported as generally well tolerated. A 2024 prospective study (n=48, 12 months) examining CJC-1295 combined with ipamorelin in adults aged 40–65 found results consistent with earlier research showing 10–15% reductions in visceral fat and modest lean mass gains over 6–12 months.

It is important to note that CJC-1295 has attracted regulatory attention. As of a 2024 FDA update, nominations for its inclusion on the significant-safety-risk list were withdrawn, but the compound remains under ongoing scrutiny, and its compounding status in the US is pending further guidance. In the UK, it is not a licensed medicine and is sold solely for research purposes.

Ipamorelin — The Selective Growth Hormone Secretagogue

Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) family and works through a different mechanism to CJC-1295. Rather than mimicking GHRH, it binds to the ghrelin receptor on pituitary cells, triggering a sharp, pulsatile release of growth hormone. Its standout characteristic — and the reason it has become arguably the most widely used GHRP in clinical and performance contexts — is its selectivity. Unlike older GHRPs such as GHRP-2 and GHRP-6, ipamorelin does not meaningfully elevate cortisol or prolactin, making it a considerably cleaner option for those concerned about the hormonal side-effects associated with less selective compounds.

CJC-1295 and ipamorelin are most commonly used together. The rationale is grounded in pituitary physiology: GHRH (mimicked by CJC-1295) increases the amplitude of growth hormone pulses, while ghrelin receptor agonists (ipamorelin) increase the frequency of those pulses. Combining the two produces synergistic GH release that more closely mirrors the body’s natural secretion pattern than either compound achieves alone.

A 2026 review published in PubMed Central, examining therapeutic peptides in gerontology, identified the CJC-1295 and ipamorelin combination as a clinically used pair for growth hormone modulation, with emerging applications in healthy ageing and muscle preservation. The same review noted that both peptides are currently banned by the World Anti-Doping Agency (WADA), which cites both performance-enhancing potential and a lack of long-term human safety data.

Sermorelin — The First-Generation GHRH Analogue

Sermorelin is a synthetic analogue of the first 29 amino acids of endogenous GHRH and was, for a time, an FDA-approved peptide for the diagnosis and treatment of growth hormone deficiency in children. That specific licence has since been withdrawn in the US, though it is still used off-label in some anti-ageing and longevity medicine practices.

As a fitness tool, sermorelin works similarly to CJC-1295 but with a shorter half-life, requiring more frequent administration. It stimulates pituitary GH release in a pulsatile, physiological pattern rather than producing the sustained elevation associated with exogenous human growth hormone, which is one reason it is often positioned as a gentler and more natural option. By elevating GH and IGF-1, sermorelin supports muscle protein synthesis, may assist in satellite cell activation for muscle repair, and promotes collagen production that benefits joint and connective tissue integrity.

Users report reduced delayed onset muscle soreness (DOMS) and improved recovery from high-intensity training sessions, though these reports are largely anecdotal and controlled human data in healthy athletes is limited. Sermorelin is considered one of the better-tolerated options in this class, with a favourable side-effect profile relative to exogenous growth hormone.

IGF-1 LR3 — Direct Anabolic Signalling

IGF-1 LR3 represents a different approach entirely. Rather than working upstream to stimulate growth hormone release, it targets the pathway downstream — acting directly at the insulin-like growth factor 1 receptor (IGF-1R) on muscle cells to drive satellite cell activation, protein synthesis, and inhibit muscle protein breakdown. Structural modifications to the native IGF-1 molecule extend its half-life from roughly 12–15 minutes to approximately 20–30 hours, giving it a substantially more potent and prolonged effect on target tissues.

In preclinical models, IGF-1 LR3 has demonstrated the ability to promote satellite cell proliferation, enhance amino acid uptake, and produce hypertrophic effects in skeletal muscle. These results have made it one of the most discussed peptides in serious bodybuilding circles. However, a notable limitation is that, as of 2026, there are no human clinical studies specifically examining its efficacy for muscle growth in healthy individuals. The human evidence that does exist relates to IGF-1 generally in the context of growth disorders and sarcopenia, not athletic performance.

The risk profile is also more significant than many other peptides in this class. Because IGF-1 LR3 bypasses the normal feedback regulation of the growth hormone axis, it may increase the risk of hypoglycaemia and carries theoretical concerns about accelerating the growth of existing pre-cancerous or cancerous cells. It is not a beginner compound and is widely considered inappropriate for unsupervised use.

Mechano Growth Factor (MGF) — The Muscle Damage Response Peptide

Mechano Growth Factor is a splice variant of IGF-1 that the body naturally produces in skeletal muscle in response to mechanical overload — in other words, in direct response to resistance training and micro-damage. Its role appears to be highly localised: rather than circulating systemically like IGF-1, MGF acts in the immediate environment of the muscle fibres that have been stressed, activating quiescent satellite cells and initiating the repair and growth cascade.

This localised action is part of what makes MGF theoretically attractive. The hypothesis is that exogenous MGF could amplify the body’s own post-training repair signal, accelerating the rate at which muscle fibres are repaired and enlarged. In animal models, localised MGF injection has produced meaningful hypertrophy. However, the synthetic MGF used in research settings has an extremely short half-life — degraded within minutes — and a PEGylated version (PEG-MGF) has been developed to extend its activity.

Human clinical data on MGF as a bodybuilding tool is essentially non-existent. It remains a compound of significant scientific interest, particularly in the field of sarcopenia research, but its practical application in gym settings is speculative.

Follistatin 344 — The Myostatin Inhibitor

Follistatin takes a conceptually distinct approach to muscle building. Rather than stimulating anabolic hormones, it works by binding and neutralising myostatin — the protein that acts as a natural brake on muscle growth. Myostatin limits how large muscles can grow; animals bred without functional myostatin genes develop dramatically enlarged muscles, a phenomenon that has been observed in cattle, mice, and even rare human cases. If myostatin could be reliably inhibited, the theory goes, the genetic ceiling on muscle mass could be raised.

The animal evidence is striking — so-called “mighty mice” studies showed doubled muscle mass with myostatin inhibition. However, translating this to humans has proven considerably more complex. The pharmaceutical myostatin inhibitor ACE-031 showed initial promise in clinical trials for muscular dystrophy before trials were discontinued due to safety concerns including nosebleeds and telangiectasias. Follistatin 344 research remains primarily preclinical, and its application in healthy individuals is entirely outside the clinical literature.

Tesamorelin — The Gold Standard for Visceral Fat Reduction

Tesamorelin holds a unique position in the peptide landscape: it is one of the few compounds in this entire category that has received FDA approval for a specific clinical indication. Approved under the brand name Egrifta, it is prescribed for the reduction of excess visceral abdominal fat in HIV patients with lipodystrophy — a metabolic condition causing abnormal fat distribution.

That clinical pedigree provides something rare in this field: genuine, controlled, peer-reviewed human data. The trials supporting tesamorelin’s approval demonstrated meaningful reductions in visceral fat, preservation of lean mass, and improvements in insulin-like growth factor 1 levels. For fitness purposes, tesamorelin works as a GHRH analogue, stimulating pulsatile GH release from the pituitary, which in turn promotes lipolysis — particularly targeting the visceral fat deposits that are most strongly linked to metabolic disease.

For people using tesamorelin outside its licensed indication — which is the situation for any fitness-motivated user — the evidence is extrapolated from its clinical dataset. That data is more robust than for most peptides in this guide, but it was generated in a specific patient population, not healthy recreational athletes.

AOD-9604 — The Fat-Burning Fragment

AOD-9604 is a synthetic peptide fragment derived from the C-terminus of the human growth hormone molecule — specifically, the portion believed to be responsible for HGH’s fat-metabolising effects. The logic behind its design is elegant: by isolating and enhancing this fragment, researchers hoped to capture the lipolytic (fat-burning) benefits of growth hormone without the insulin resistance and other systemic effects that can accompany full HGH use.

In preclinical studies, AOD-9604 has demonstrated the ability to stimulate lipolysis and inhibit lipogenesis (the formation of new fat cells), particularly targeting adipose tissue. It has been shown to work through beta-adrenergic receptors and does not appear to affect blood glucose or insulin sensitivity in the same way that HGH does — a notable advantage. Clinical trials for obesity were conducted in the 2000s under the brand name Metabolase, though the compound ultimately did not reach approval for that indication. The phase 2 trials were considered encouraging but not sufficient for regulatory approval.

AOD-9604 is frequently described as one of the most targeted fat-loss peptides available, and its relatively benign side-effect profile has made it popular in supervised wellness protocols. It is particularly favoured for addressing stubborn body fat that resists conventional diet and exercise.

MOTS-c — The Mitochondrial Exercise Mimetic

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is one of the most intriguing peptides to emerge from recent research. It is not a synthetic creation designed in a laboratory — it is a naturally occurring peptide encoded within the mitochondrial genome, sometimes described as a mitochondrial-derived peptide (MDP). It acts as a metabolic regulator, primarily through activation of AMPK (AMP-activated protein kinase), a central sensor of cellular energy status.

By activating AMPK, MOTS-c promotes the uptake and oxidation of glucose and fatty acids, enhances insulin sensitivity, and improves the efficiency with which cells convert stored energy into usable fuel. A 2025 PubMed-indexed study (PMID: 40035775) examined MOTS-c’s role in promoting glycolysis via the AMPK–HIF-1α–PFKFB3 pathway, providing mechanistic insight into how it modulates cellular energy production. Animal research has shown that MOTS-c administration mimics some of the beneficial metabolic effects of exercise — earning it the informal label of “exercise mimetic”.

Human data remains limited and primarily observational, but MOTS-c has attracted serious academic interest as a longevity and metabolic health compound. It is often stacked with tesamorelin and AOD-9604 in supervised fat-loss protocols.

BPC-157 — The Regenerative Gastric Peptide

Body Protection Compound 157 (BPC-157) is a synthetic pentadecapeptide — a 15-amino-acid chain — derived from a protective protein found in gastric juice. It was originally investigated for its cytoprotective and gut-healing properties, but its apparent ability to accelerate tissue repair across multiple systems has made it one of the most discussed recovery peptides in sport and fitness contexts.

A 2025 systematic review published in the HSS Journal examined 36 studies spanning 1993 to 2024. Results in animal models suggested that BPC-157 may promote the healing of muscle, tendon, ligament, and bone tissue. A review published in the International Journal of Molecular Sciences in 2026 noted that BPC-157 may support angiogenesis (new blood vessel formation), collagen production, and the modulation of inflammatory responses.

A 2026 systematic review of injectable peptide therapies in orthopaedics and sports medicine, published in a SAGE Journals publication, concluded that BPC-157 demonstrated potential benefits in tendon and muscle repair — but stated clearly that “these findings are largely unvalidated in human trials.” A single human case series reported that 7 of 12 people with chronic knee pain experienced relief for over six months after a single BPC-157 injection, but the study lacked a control group and suffers from significant methodological limitations.

An important regulatory note: the FDA’s September 2024 update listed BPC-157 under Category 2, meaning it is considered to present significant safety risks for compounding purposes in the United States. In the UK, BPC-157 is not a controlled substance but may only be sold for laboratory research. The US Anti-Doping Agency (USADA) prohibits it in competitive sport.

TB-500 (Thymosin Beta-4 Fragment) — The Tissue Regeneration Peptide

Thymosin Beta-4 (TB-4) is a naturally occurring protein found in virtually all human cells, where it plays a central role in actin polymerisation — the dynamic restructuring of the cellular skeleton that is essential for cell migration, wound healing, and tissue repair. TB-500 is a synthetic fragment of TB-4 believed to retain much of the biological activity of the full protein while being more practical to synthesise.

In preclinical models, TB-4 and TB-500 have demonstrated promotion of angiogenesis, acceleration of wound closure, and enhanced repair of cardiac, skeletal muscle, and connective tissue. The 2026 systematic review in orthopaedics and sports medicine (Mayfield et al., SAGE Journals) concluded that “TB-4 and its derivative TB-500 promoted angiogenesis and tissue repair in preclinical models, but human orthopaedic data are lacking.” Both compounds are currently on the WADA prohibited list.

TB-500 is frequently used in combination with BPC-157 — a pairing sometimes nicknamed the “Wolverine Stack” — with the rationale that the two compounds address tissue repair through complementary mechanisms. BPC-157 appears to focus more on tendon and ligament healing and modulation of inflammatory signalling, while TB-500 targets cellular mobility and angiogenesis.

GHK-Cu — Copper Peptide for Tissue Repair and Inflammation

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding peptide found in human plasma, saliva, and urine. Levels decline with age, and this decline has been linked to reduced tissue repair capacity and increased inflammatory tone. GHK-Cu has been extensively studied in the context of wound healing, skin regeneration, and anti-inflammatory activity.

In a fitness and performance context, the interest in GHK-Cu centres on its ability to upregulate collagen synthesis, promote angiogenesis, reduce markers of oxidative stress, and potentially support the repair of connective tissue — joints, tendons, and fascia that are subjected to repetitive loading in training. The 2026 systematic review of injectable peptide therapies (Mayfield et al.) included GHK-Cu in its analysis, acknowledging its regenerative properties alongside recognition that large-scale human orthopaedic trials are lacking.

GHK-Cu is also widely used in topical skincare — it has a reasonable body of evidence supporting collagen induction when applied to the skin — and this application has a more established evidence base than its systemic or injectable uses in athletic recovery.

GHRP-2 — Potent but Non-Selective GH Release

GHRP-2 is one of the most potent ghrelin receptor agonists studied in peptide research, producing strong pulsatile GH release. Studies in animal models — including a PubMed-indexed study in yaks with growth retardation — have shown GHRP-2’s ability to elevate GH, IGF-1, and reduce markers of muscle protein degradation, including the E3 ubiquitin ligases Atrogin-1 and MuRF1. GHRP-2 can also reduce these degradation markers and stimulate muscle repair in pathological scenarios.

However, GHRP-2 lacks the selectivity of ipamorelin. It produces dose-dependent elevations in cortisol and prolactin — stress and reproductive hormones — which are undesirable in the context of performance and body composition. The cortisol elevation, in particular, is counterproductive for hypertrophy, as cortisol promotes muscle protein breakdown. For this reason, GHRP-2 has been largely superseded by ipamorelin in clinical settings.

GHRP-6 — Strong GH Stimulant with Appetite Side Effects

GHRP-6 is another first-generation ghrelin mimetic, notable for producing robust GH pulses but also for a significant increase in appetite — a direct consequence of its activity at ghrelin receptors, which play a role in hunger signalling. For individuals seeking to maximise caloric intake during a muscle-building phase, this side effect may be a feature rather than a problem. For those trying to maintain a caloric deficit, it is a clear drawback.

A 2024 peer-reviewed study (Berlanga-Acosta et al., Frontiers in Pharmacology) examined GHRP-6’s role in preventing doxorubicin-induced cardiomyopathy, demonstrating prosurvival mechanisms including antioxidant defence upregulation and preservation of mitochondrial integrity — highlighting that GHRPs have potential applications well beyond fitness that continue to generate genuine scientific interest.

Hexarelin — The Most Potent GHRP

Hexarelin (also known as examorelin) is considered the most potent growth hormone-releasing peptide in the GHRP class. It produces the largest GH pulses of any compound in this category and has additionally been studied for cardioprotective properties — there is a body of research suggesting hexarelin may act on receptors in cardiac tissue to reduce myocardial injury and improve cardiac function independently of its GH-releasing activity.

The downside is that hexarelin is associated with rapid desensitisation — the pituitary becomes less responsive to it more quickly than with ipamorelin or GHRP-2 — and it also elevates cortisol and prolactin. For these reasons, it is typically reserved for short, targeted protocols post-injury or post-surgery rather than sustained performance use. Like all compounds in this guide, it is a research chemical in the UK with no licensed indication for fitness purposes.

How Does the Evidence Compare? An Honest Assessment

One of the consistent findings when reviewing the research is how large the gap is between the excitement generated by preclinical data and the actual human trial evidence. The table below provides a clear comparison to help set realistic expectations.

Common Peptide Stacks for Different Fitness Goals

Experienced researchers and clinicians rarely work with single peptides in isolation. The rationale for combining compounds is rooted in their complementary mechanisms — using two peptides that work through different pathways can produce synergistic effects that neither achieves alone. The following combinations appear most frequently in the published clinical and academic literature, as well as in supervised clinical practice.

It should be emphasised clearly: the following represents what is discussed in research and clinical contexts, not recommendations for self-administration. All of these combinations involve compounds that are not licensed for fitness use in the UK and should only be considered under qualified medical supervision.

UK Legal Status, Safety Considerations, and the MHRA Framework

Understanding the regulatory position of peptides in the UK is essential reading for anyone interested in this topic. The picture is more nuanced than a simple legal or illegal binary, and getting it wrong can have genuine consequences.

As of 2026, most research peptides — including BPC-157, TB-500, GHK-Cu, IGF-1 LR3, and the GHRH analogues — are not scheduled under the Misuse of Drugs Act 1971. Possession for personal use is therefore not a criminal offence in the same way it would be for a Class A drug. However, this does not make them freely available for human use.

The Human Medicines Regulations 2012, overseen by the Medicines and Healthcare products Regulatory Agency (MHRA), make it illegal to sell or supply any compound for human medicinal purposes without a marketing authorisation. Selling peptides as supplements, health products, or treatments — even without making direct therapeutic claims — can bring a vendor into conflict with MHRA enforcement. The MHRA has taken enforcement action against suppliers marketing peptides for human use without appropriate licensing.

The practical result is that legitimate UK suppliers sell these compounds labelled as “for research use only” and “not for human consumption.” This is not purely a marketing disclaimer — it is the legal framework that makes the supply of these products lawful. Any supplier providing dosing instructions for human use, making health claims, or otherwise presenting peptides as consumer products is operating in clear violation of the regulations.

What the Evidence Says — and What It Doesn’t

It is worth being direct about something that can get lost in the enthusiasm surrounding peptides: even the compounds with the strongest mechanistic rationale and most compelling preclinical data have remarkably little human trial evidence in healthy exercising individuals. A 2026 Mayo Clinic statement — updated specifically in relation to bodybuilding peptides — described them as lacking “rigorous safety data” and noted they “are not recommended” for performance use. A 2025 NIH review flagged the widespread sale of unapproved “research peptides” online, noting that many lack verified purity testing.

This does not mean the science is without value. The mechanistic understanding of how these compounds interact with growth hormone, IGF-1, myostatin, and tissue repair pathways is genuinely advancing. Tesamorelin has proven clinical utility. The GH secretagogue class has legitimate applications in age-related GH decline under medical supervision. And the preclinical data on BPC-157 and TB-500 is sufficiently interesting that several research groups are now pursuing human trials.

The honest summary is this: the most impactful things an individual can do for muscle building, fat loss, and recovery remain progressive resistance training, adequate protein intake (1.6–2.2g per kg of body weight per day, per current ISSN guidelines), sufficient quality sleep, and consistent caloric management. Peptides, at best, offer targeted physiological nudges that may provide modest incremental advantages — but they sit on top of, not in place of, these fundamentals.

Emerging Peptides to Watch in 2026 and Beyond

The peptide research landscape is evolving rapidly. Several compounds are attracting increasing scientific and clinical attention that, while too early to include among established fitness peptides, may become more relevant in the coming years.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist that demonstrated 22–24% body fat reduction in clinical trials, as reported in Nature Medicine (2024). It is primarily positioned as a next-generation metabolic medicine rather than a fitness compound, but its body composition effects are substantial.

Epitalon is a tetrapeptide derived from the pineal gland that has attracted interest in gerontology for its apparent effects on telomere biology and reduction of oxidative damage markers. A 2026 PMC review on therapeutic peptides in gerontology identified it among peptides being studied for healthy ageing applications, though clinical translation remains early.

Selank and Semax are neuropeptides with adaptogenic properties — they modulate stress responses and may support cognitive performance and recovery from training-related psychological fatigue. Both are used in clinical settings in Russia and are attracting broader research interest.

References and Citations